

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Currently amended) A method of treating a myocardial infarction~~reducing or preventing oxidative stress associated cell death~~, the method comprising:

~~selecting an individual diagnosed as having or being at risk of contracting a disorder characterized by excessive oxidative stress associated cell death; and~~

administering to ~~an~~the individual in need thereof a therapeutically effective amount of a composition comprising an N-phenyl-2-pyrimidine-amine ~~in an amount effective to reduce or prevent oxidative stress associated cell death in the individual.~~

2. (Original) The method of claim 1, wherein the N-phenyl-2-pyrimidine-amine is 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino-]-phenyl] benzamide methanesulfonate.

3-20. (Cancelled)

21. (Currently amended) The method of claim 1-17, wherein the composition is co-administered in combination with a thrombolytic that is administered concurrently with, before, or after administration of the N-phenyl-2-pyrimidine-amine ~~further comprising administering to~~

~~the individual a second therapeutic compound, wherein the second therapeutic compound reduces or prevents symptoms of the disorder.~~

22. (Currently amended) The method of claim ~~1-21~~, wherein the composition is co-administered in combination with an anticoagulant that is administered concurrently with, before, or after administration of the N-phenyl-2-pyrimidine-amine ~~the second therapeutic compound is a thrombolytic or an anticoagulant.~~

23-47. (Cancelled)

48. (New) The method of claim 21, wherein the thrombolytic is anisoylated plasminogen streptokinase activator complex (APSAC), plasmin, urokinase, pro-urokinase, streptokinase, or tissue plasminogen activator.

49. (New) The method of claim 48, wherein the thrombolytic is tissue plasminogen activator.

50. (New) The method of claim 22, wherein the anticoagulant is heparin.

51. (New) A method of treating a stroke, the method comprising administering to an individual in need thereof a therapeutically effective amount of a composition comprising an N-phenyl-2-pyrimidine-amine.

52. (New) The method of claim 51, wherein the composition is co-administered in combination with a thrombolytic that is administered concurrently with, before, or after administration of the N-phenyl-2-pyrimidine-amine.

53. (New) The method of claim 51, wherein the composition is co-administered in combination with an anticoagulant that is administered concurrently with, before, or after administration of the N-phenyl-2-pyrimidine-amine.

54. (New) The method of claim 52, wherein the thrombolytic is anisoylated plasminogen streptokinase activator complex (APSAC), plasmin, urokinase, pro-urokinase, streptokinase, or tissue plasminogen activator.

55. (New) The method of claim 54, wherein the thrombolytic is tissue plasminogen activator.

56. (New) The method of claim 53, wherein the anticoagulant is heparin.

57. (New) The method of claim 21, wherein the N-phenyl-2-pyrimidine-amine is 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino-]-phenyl] benzamide methanesulfonate.

58. (New) The method of claim 22, wherein the N-phenyl-2-pyrimidine-amine is 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino-]-phenyl] benzamide methanesulfonate.

59. (New) The method of claim 48, wherein the N-phenyl-2-pyrimidine-amine is 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino-]-phenyl] benzamide methanesulfonate.

60. (New) The method of claim 49, wherein the N-phenyl-2-pyrimidine-amine is 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino-]-phenyl] benzamide methanesulfonate.

61. (New) The method of claim 50, wherein the N-phenyl-2-pyrimidine-amine is 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino-]-phenyl] benzamide methanesulfonate.

62. (New) The method of claim 51, wherein the N-phenyl-2-pyrimidine-amine is 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino-]-phenyl] benzamide methanesulfonate.

63. (New) The method of claim 52, wherein the N-phenyl-2-pyrimidine-amine is 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino-]-phenyl] benzamide methanesulfonate.

64. (New) The method of claim 53, wherein the N-phenyl-2-pyrimidine-amine is 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino-]-phenyl] benzamide methanesulfonate.

65. (New) The method of claim 54, wherein the N-phenyl-2-pyrimidine-amine is 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino-]-phenyl] benzamide methanesulfonate.

66. (New) The method of claim 55, wherein the N-phenyl-2-pyrimidine-amine is 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino-]-phenyl] benzamide methanesulfonate.

67. (New) The method of claim 56, wherein the N-phenyl-2-pyrimidine-amine is 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino-]-phenyl] benzamide methanesulfonate.